Amplification of the proto-oncogene MYCN has been used for many years in these patients as a reliable marker for defining high-risk disease [406], but only recently, recurrent genomic rearrangements proximal of the TERT gene have been reported in NBL, defining a subgroup of high-risk tumours with a particular poorer outcome [54,340]. The gene discussed is MYCN; the disease is neoplasm.